share_log

Mangoceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Cohen Jacob D.

Mangoceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Cohen Jacob D.

Mangoceuticals | 4:持股变动声明-高管 Cohen Jacob D.
美股SEC公告 ·  08/27 19:45

Moomoo AI 已提取核心信息

Jacob D. Cohen, CEO of Mangoceuticals, completed a transaction involving the company's common stock on August 26, 2024. The action, classified as a bona fide gift, consisted of both acquiring and disposing of 800,000 shares at no cost. Following the transaction, Cohen's direct holdings in Mangoceuticals common stock amounted to 9,075,000 shares.
Jacob D. Cohen, CEO of Mangoceuticals, completed a transaction involving the company's common stock on August 26, 2024. The action, classified as a bona fide gift, consisted of both acquiring and disposing of 800,000 shares at no cost. Following the transaction, Cohen's direct holdings in Mangoceuticals common stock amounted to 9,075,000 shares.
曼果生物公司CEO Jacob D. Cohen于2024年8月26日完成了一笔涉及公司普通股的交易。此举被归类为真正的礼物,包括无偿获取和处置80万股。交易结束后,cohen在曼果生物公司的直接持股股数达到了907.5万股。
曼果生物公司CEO Jacob D. Cohen于2024年8月26日完成了一笔涉及公司普通股的交易。此举被归类为真正的礼物,包括无偿获取和处置80万股。交易结束后,cohen在曼果生物公司的直接持股股数达到了907.5万股。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息